Tyrosine kinase inhibitor therapy or transplant in children with Philadelphia chromosome-positive acute lymphoblastic leukaemia: striking the balance
-
Published:2018-12
Issue:12
Volume:5
Page:e606-e607
-
ISSN:2352-3026
-
Container-title:The Lancet Haematology
-
language:en
-
Short-container-title:The Lancet Haematology
Reference10 articles.
1. Imatinib treatment of paediatric Philadelphia chromosome-positive acute lymphoblastic leukaemia (EsPhALL2010): a prospective, intergroup, open-label, single-arm clinical trial;Biondi;Lancet Haematol,2018
2. Long-term follow-up of imatinib in pediatric Philadelphia chromosome-positive acute lymphoblastic leukemia: Children's Oncology Group study AALL0031;Schultz;Leukemia,2014
3. Alternating versus concurrent schedules of imatinib and chemotherapy as front-line therapy for Philadelphia-positive acute lymphoblastic leukemia (Ph+ ALL);Wassmann;Blood,2006
4. Imatinib after induction for treatment of children and adolescents with Philadelphia-chromosome-positive acute lymphoblastic leukaemia (EsPhALL): a randomised, open-label, intergroup study;Biondi;Lancet Oncol,2012
5. Minimal residual disease in adult ALL: technical aspects and implications for correct clinical interpretation;Bruggemann;Blood Adv,2017
Cited by
3 articles.
订阅此论文施引文献
订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献